Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled randomized clinical trial
Ashraf et al.,
Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK): A multi-center placebo-controlled..,
Phytotherapy Research, doi:10.1002/ptr.7640 (date from earlier preprint), HNS-COVID-PK, NCT04347382
RCT with 157 patients treated with honey and nigella sativa, and 156 control patients, showing significantly faster recovery and viral clearance.
Honey (1gm/kg/day) plus encapsulated nigella sativa seeds (80mg/kg/day) orally in 2-3 divided doses daily for up to 13 days.
risk of death, 81.9% lower, RR 0.18, p = 0.01, treatment 2 of 157 (1.3%), control 11 of 156 (7.1%), NNT 17, all cases.
|
risk of death, 67.1% lower, RR 0.33, p = 0.49, treatment 0 of 107 (0.0%), control 1 of 103 (1.0%), NNT 103, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), moderate cases.
|
risk of death, 78.8% lower, RR 0.21, p = 0.03, treatment 2 of 50 (4.0%), control 10 of 53 (18.9%), NNT 6.7, severe cases.
|
risk of no recovery, 83.6% lower, HR 0.16, p < 0.001, treatment 107, control 103, inverted to make HR<1 favor treatment, moderate cases.
|
risk of no recovery, 75.2% lower, HR 0.25, p < 0.001, treatment 50, control 53, inverted to make HR<1 favor treatment, severe cases.
|
risk of no viral clearance, 81.9% lower, HR 0.18, p < 0.001, treatment 107, control 103, inverted to make HR<1 favor treatment, moderate cases.
|
risk of no viral clearance, 76.9% lower, HR 0.23, p < 0.001, treatment 50, control 53, inverted to make HR<1 favor treatment, severe cases.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|

Ashraf et al., 3 Nov 2020, Randomized Controlled Trial, placebo-controlled, Pakistan, peer-reviewed, 29 authors, study period 30 April, 2020 - 29 July, 2020, this trial uses multiple treatments in the treatment arm (combined with honey) - results of individual treatments may vary, trial
NCT04347382 (history) (HNS-COVID-PK).
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20217364; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
Honey and Nigella sativa against COVID-19 in Pakistan (HNS-COVID-PK):
A multi-center placebo-controlled randomized clinical trial
Sohaib Ashraf1,2, Shoaib Ashraf 2, Moneeb Ashraf3, Muhammad Ahmad Imran3, Larab
Kalsoom3, Uzma Nasim Siddiqui3, Iqra Farooq3, Zaighum Habib, Sidra Ashraf, Muhammad
Ghufran, Muhammad Kiwan Akram, Nighat Majeed, Zain-ul-Abdin, Rutaba Akmal, Sundas
Rafique, Khawar Nawaz, Muhammad Ismail K Yousaf, Sohail Ahmad, Muhammad Sarmad
Shahab, Muhammad Faisal Nadeem, Muhammad Azam, Hui Zheng, Amber Malik, Mahmood
Ayyaz, Talha Mahmud, Qazi Abdul Saboor, Ali Ahmad, Muhammad Ashraf, Mateen Izhar for
the COALITION COVID-19 Shaikh Zayed Ω
1 Correspondence
to:
Dr Sohaib Ashraf: Department of Cardiology, Shaikh Zayed Post-Graduate Medical
Complex, Lahore, 54600, Pakistan.
sohaib-ashraf@outlook.com
2 Joint
3
First Author
Joint Second Author
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20217364; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
Ω COALITION COVID-19 Shaikh Zayed:
Abubakar Hilal, Arz Muhammad, Zeeshan Shaukat, Ayesha Khaqan, Kanwal Hayat, Shahroze Arshad,
Muhammad Hassan, Abeer-bin-Awais, Ammara Ahmad, Tayyab Mughal, Abdur Rehman Virk,
Muhammad Umer, Muhammad Suhail, Sibgha Zulfiqar, Saulat Sarfraz, Muhammad Imran Anwar,
Ayesha Humayun
Affiliations:
1. Department of Cardiology, Shaikh Zayed Post-Graduate Medical Complex, Lahore,
Pakistan.
i. S Ashraf, MBBS
ii. Z U Abdin, MBBS
iii. A Hilal, MBBS
iv. A Muhammad, MBBS
v. Z Shaukat, MBBS
vi. A Khaqan, MBBS
vii. K Hayat, M.Phil
viii. Prof. Q A Saboor
2. Department of Pathobiology, Riphah University, Lahore, Pakistan
i. Sh Ashraf, PhD
3. Department of Pharmacology, Kingedward Medical University, Mayo Hospital, Lahore,
Pakistan.
i. M Ashraf, MBBS
4. Department of Microbiology, Shaikh Zayed Post-Graduate Medical Institute, Lahore,
Pakistan.
i. M A Imran, MBBS
medRxiv preprint doi: https://doi.org/10.1101/2020.10.30.20217364; this version posted November 30, 2020. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY 4.0 International license .
ii. Prof. M Izhar, PhD
5. Division of Telemedicine, Doctor’s Lounge, Lahore, Pakistan.
i. M A Imran, MBBS
ii. M S Shahab, MBBS
iii. I Farooq, MBBS
iv. S Rafique, MBBS
6. Department of Internal Medicine, Services Institute of Medical Sciences, Lahore,
Pakistan.
i. L Kalsoom, MBBS
ii. N Majeed, MBBS
7. Department of Medicine, Port Macquarie Base Hospital, New South Wales, Australia.
i. U N Siddique, MBBS
8. Department of Internal Medicine, Shaikh Zayed Post-Graduate Medical Institute, Lahore,
Pakistan.
i. S Arshad, MBBS
ii. M Hassan, MBBS
iii. U N Siddique, MBBS
9...
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit